Clinical trials: Unresectable Cancer
Brain and Central Nervous System Tumors
Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of hydroxyurea in treating patients who have recurrent…
- Trial name
- NCT00006119
- Testing
- hydroxyurea
- Where
- 5 sites in France
- Sponsor
- UNICANCER
Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma
This trial studies how well yttrium Y 90 glass microspheres work in treating patients with hepatocellular carcinoma that cannot be removed by surgery.
- Conditions
- Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT01176604
- Testing
- Yttrium Y 90 Glass Microspheres
- Where
- United States
- Volunteers
- 299 people
- Sponsor
- M.D. Anderson Cancer Center
Brain Tumor, Central Nervous System Tumor
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
RATIONALE: Sodium thiosulfate may reduce or prevent hearing loss in young patients receiving cisplatin for cancer. It is not yet known whether sodium thiosulfate is more effective than no additional treatment in preventing…
- Conditions
- Brain Tumor, Central Nervous System Tumor, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
- Trial name
- NCT00716976
- Testing
- sodium thiosulfate, examination
- Where
- 76 sites in United States, Australia and 1 more
- Volunteers
- 131 people
- Sponsor
- Children's Oncology Group
Pancreatic Neoplasms
LYNPARZA Pancreas Cancer Japan Post-Marketing Surveillance (PMS)
To collect and characterise the incidence of adverse events related to the safety specifications of the maintenance treatment after platinum-based chemotherapy in patients with BRCA mutated pancreatic cancer under the actual…
- Trial name
- NCT04889404
- Where
- 60 sites in Japan
- Volunteers
- 130 people
- Sponsor
- AstraZeneca
Neuroblastoma
Combination Chemotherapy in Treating Children With Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003093
- Testing
- filgrastim, sargramostim, carboplatin
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 573 people
- Sponsor
- Children's Oncology Group
Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Adding Spatially Fractionated Radiation Therapy to Standard Palliative Radiation for Improving Disease-Related Symptoms in Patients With Unresectable Solid Tumors
This clinical trial evaluates whether adding spatially fractionated radiation therapy (SFRT) to standard palliative external beam radiation therapy (EBRT) improves disease-related symptoms in patients with solid tumors that…
- Conditions
- Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm, Unresectable Solid Tumor, Malignant Tumor
- Trial name
- NCT07856394
- Testing
- Electronic Health Record Review, External Beam Radiation Therapy, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Colorectal Cancer
A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma
This is an observational study designed to follow patients with metastatic or locally advanced and unresectable colorectal cancer who are receiving Avastin in combination with chemotherapy and whose cancer has been either…
- Trial name
- NCT00097578
- Where
- United States
- Volunteers
- 1,953 people
- Sponsor
- Genentech, Inc.
Malignant Peripheral Nerve Sheath Tumors (MPNST), Sarcoma
SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
Phase 1: To assess the safety, tolerability, and maximum tolerated dose (MTD)/ recommended dose of ganetespib when administered in combination with sirolimus in patients with refractory or relapsed sarcomas including unresectable…
- Trial name
- NCT02008877
- Testing
- ganetespib, Sirolimus
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Advanced or Recurrent Colorectal Cancer
Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)
The efficacy and safety of panitumumab (Vectibix) in the routine clinical setting will be studied. Specifically, information will be collected on the following as events of interest: skin disorders, interstitial lung disease…
- Trial name
- NCT02089737
- Testing
- Panitumumab
- Volunteers
- 3,091 people
- Sponsor
- Takeda
Neuroblastoma
Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma
RATIONALE: Monoclonal antibodies, such as 3F8, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00450307
- Testing
- monoclonal antibody 3F8, sargramostim
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumor, Urethral Cancer
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
The goal of this clinical research study is to find the highest tolerable dose of Gemzar® (gemcitabine) and Adriamycin® (doxorubicin) that can be given together with Velcade® (bortezomib) in patients with urothelial cancer or…
- Trial name
- NCT00479128
- Testing
- Bortezomib, Gemcitabine, Doxorubicin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Non-Small-Cell Lung
Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA)
First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy in Asia Area
- Trial name
- NCT04529564
- Where
- 12 sites in Taiwan
- Volunteers
- 106 people
- Sponsor
- AstraZeneca
Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
This phase II trial studies how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread from where it first…
- Conditions
- Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma
- Trial name
- NCT04394858
- Testing
- Biospecimen Collection, Computed Tomography with Contrast, Magnetic Resonance Imaging
- Where
- 163 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, C-KIT Tyrosine Kinase Protein Overexpression
Ipilimumab and Imatinib Mesylate in Advanced Cancer
This phase I trial studies the side effects and best dose of ipilimumab and imatinib mesylate in treating patients with solid tumors that have spread to other places in the body or cannot be removed by surgery.
- Conditions
- Advanced Malignant Solid Neoplasm, C-KIT Tyrosine Kinase Protein Overexpression, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Gastrointestinal Stromal Tumor
- Trial name
- NCT01738139
- Testing
- Imatinib Mesylate, Ipilimumab
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN2810, also known as cemiplimab (each individually called a "study drug" or called…
- Trial name
- NCT05352672
- Testing
- Fianlimab, Cemiplimab, Pembrolizumab
- Where
- 210 sites in United States, Argentina and 22 more
- Volunteers
- 1,546 people
- Sponsor
- Regeneron Pharmaceuticals
Melanoma
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with…
- Trial name
- NCT03635983
- Testing
- NKTR-214, Nivolumab
- Where
- 167 sites in United States, Argentina and 25 more
- Volunteers
- 783 people
- Sponsor
- Bristol-Myers Squibb
Unresectable, Locally Advanced
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in…
- Conditions
- Unresectable, Locally Advanced, Metastatic Cancers, Relapsed/Refractory Lymphomas
- Trial name
- DAHLIA (NCT06678659)
- Testing
- REC-1245
- Where
- 7 sites in United States, Canada
- Volunteers
- 170 people
- Sponsor
- Recursion Pharmaceuticals Inc.
Sarcoma
Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining gemcitabine with docetaxel may kill more tumor cells.
- Trial name
- NCT00073983
- Testing
- filgrastim, pegfilgrastim, docetaxel
- Volunteers
- 54 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Melanoma, Skin Cancer
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
The purpose of this study is to see if BMS-986205 combined with nivolumab, compared to nivolumab by itself, is more effective in treating Melanoma that has spread or is unable to be removed by surgery, and has not previously been…
- Trial name
- NCT03329846
- Testing
- BMS-986205, Nivolumab
- Where
- 63 sites in United States, Australia and 14 more
- Volunteers
- 20 people
- Sponsor
- Bristol-Myers Squibb
Hepatic Malignant Neoplasm Primary Non-Resectable
Registry Protocol- Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic Malignancy
Collection of Safety, Efficacy and Resource Utilization Information in Patients Who Have Received Melphalan PHP with the Delcath Hepatic Delivery System for the Treatment of Unresectable Hepatic Malignancy
- Trial name
- NCT03266042
- Where
- 2 sites in United Kingdom
- Volunteers
- 200 people
- Sponsor
- Delcath Systems Inc.